Biologics – Page 3 – Pharma.Tips

Biologic cell culture contamination event during commercial manufacturing campaign: single-use systems risk controls, leachables review, and supplier oversight actions

The first step in identifying a biologic cell culture contamination event is recognizing the symptoms or signals that indicate a potential problem. These include:Click to read the full article.

Biologic freeze-thaw cycle deviation during deviation investigation board review: single-use systems risk controls, leachables review, and supplier oversight actions

Identifying symptoms or signals indicative of a deviation is the first step in any investigation. Common symptoms that may signal a freeze-thaw cycle deviation include:Click to read the full article.

Biologic glycosylation shift (CQAs) outside trend after equipment qualification update: investigation strategy aligned to FDA/EMA expectations and comparability principles

Identifying symptoms indicative of a potential glycosylation shift is critical for initiating a timely investigation. Some common signals include:Click to read the full article.

Biologic viral clearance validation gap during PPQ / process validation: how to document root cause when multiple unit operations are involved

The first step in identifying a biologic viral clearance validation gap involves recognizing relevant symptoms or signals that indicate potential deviations in the manufacturing process. Common symptoms to monitor include:Click…

Biologic host cell protein (HCP) OOS during commercial manufacturing campaign: single-use systems risk controls, leachables review, and supplier oversight actions

Identifying symptoms and signals that indicate potential HCP OOS results is the first step in effectively managing the issue. Common signs include:Click to read the full article.

Biologic cold chain excursion impact during deviation investigation board review: investigation strategy aligned to FDA/EMA expectations and comparability principles

Cold chain excursions can manifest as various symptoms within the manufacturing and quality control environments. Identifying these symptoms promptly is crucial for initiating an effective investigation. Here are some common…

Biologic host cell protein (HCP) OOS after upstream media/raw material change: single-use systems risk controls, leachables review, and supplier oversight actions

Identifying symptoms or signals indicating potential issues in upstream processing is critical for timely intervention. Common signals that may indicate a problem with HCPs include:Click to read the full article.

Biologic charge variant shift (CEX) OOS after filling line intervention: data integrity checks for bioassays and analytical similarity packages

“`html Addressing OOS Results from Biologic Charge Variant Shift (CEX) Post-Filling Line Intervention In the highly regulated world of pharmaceutical manufacturing, an out-of-specification (OOS) result stemming from a biologic charge…

Biologic stability failure (real-time/accelerated) during CPV trending review: viral safety and contamination response plan with inspection-ready evidence

Symptoms or signals of biologic stability failures typically manifest as deviations in stability data during CPV trending reviews. It is vital to monitor both real-time and accelerated conditions closely. Common…

Biologic upstream yield drop (OOT) during commercial manufacturing campaign: CAPA package with CQA/CPP risk assessment and effectiveness verification

Identifying early signals of a yield drop in a biologic manufacturing campaign is crucial for timely response and minimization of impacts. Symptoms can manifest in several forms, including:Click to read…

Biologic upstream yield drop (OOT) during FDA/EMA inspection readiness: viral safety and contamination response plan with inspection-ready evidence

Identifying symptoms or signals on the manufacturing floor or in the laboratory is pivotal in promptly addressing a drop in biologic upstream yield. Key symptoms may include:Click to read the…

Biologic bioburden excursion pre-sterile filtration after filling line intervention: CAPA package with CQA/CPP risk assessment and effectiveness verification

The initial step in addressing a bioburden excursion is recognizing the symptoms that signal a problem. Common indicators might include:Click to read the full article.